Products
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
BAYER AG
π©πͺ
Germany
Country
π©πͺ
Germany
Ownership
Public
Established
1863-08-01
Employees
99.7K
Market Cap
$30.1B
Website
http://www.bayer.com
Clinical Trials
Related News
Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma
Phase 2
Completed
Conditions
Cancer
Melanoma
Interventions
Drug: Placebo
Drug: Sorafenib (Nexavar, BAY43-9006)
Drug: Dacarbazine
Subscribe
First Posted Date
2005-05-17
Last Posted Date
2015-06-08
Lead Sponsor
Bayer
Target Recruit Count
101
Registration Number
NCT00110994
Subscribe
Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma
Phase 3
Completed
Conditions
Carcinoma, Renal Cell
Interventions
Drug: Sorafenib (Nexavar, BAY43-9006)
Subscribe
First Posted Date
2005-05-17
Last Posted Date
2014-08-06
Lead Sponsor
Bayer
Target Recruit Count
2567
Registration Number
NCT00111020
Subscribe
A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
Phase 3
Completed
Conditions
Melanoma
Interventions
Drug: Sorafenib (Nexavar, BAY43-9006)
Drug: Carboplatin/Paclitaxel
Drug: Placebo
Subscribe
First Posted Date
2005-05-17
Last Posted Date
2014-10-31
Lead Sponsor
Bayer
Target Recruit Count
270
Registration Number
NCT00111007
Subscribe
Research Study for Patients With Metastatic Renal Cell Carcinoma
Phase 2
Terminated
Conditions
Carcinoma, Renal Cell
Interventions
Drug: Nexavar (Sorafenib, BAY43-9006)
Drug: Placebo
Subscribe
First Posted Date
2005-05-09
Last Posted Date
2013-10-11
Lead Sponsor
Bayer
Target Recruit Count
1
Registration Number
NCT00110344
Subscribe
A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma
Phase 2
Completed
Conditions
Carcinoma, Hepatocellular
Interventions
Drug: Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin
Drug: Doxorubicin/Placebo
Subscribe
First Posted Date
2005-04-22
Last Posted Date
2014-10-31
Lead Sponsor
Bayer
Target Recruit Count
96
Registration Number
NCT00108953
Subscribe
A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Phase 3
Completed
Conditions
Carcinoma, Hepatocellular
Interventions
Drug: Placebo
Drug: Sorafenib (Nexavar, BAY43-9006)
Subscribe
First Posted Date
2005-03-15
Last Posted Date
2014-10-31
Lead Sponsor
Bayer
Target Recruit Count
602
Registration Number
NCT00105443
Subscribe
Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women
Phase 3
Completed
Conditions
Hypertension
Postmenopause
Interventions
Drug: Angeliq (Drospirenone/17Γ-estradiol, BAY86-4891)
Drug: Placebo
Subscribe
First Posted Date
2005-01-24
Last Posted Date
2014-12-15
Lead Sponsor
Bayer
Target Recruit Count
750
Registration Number
NCT00102141
Subscribe
BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)
Phase 2
Completed
Conditions
Carcinoma, Non-Small Cell Lung
Cancer
Interventions
Drug: Sorafenib (Nexavar, BAY43-9006)
Subscribe
First Posted Date
2005-01-11
Last Posted Date
2013-10-30
Lead Sponsor
Bayer
Target Recruit Count
52
Registration Number
NCT00101413
Subscribe
BAY43-9006 - Phase II in Advanced Breast Cancer
Phase 2
Completed
Conditions
Breast Neoplasms
Breast Cancer
Interventions
Drug: Sorafenib (Nexavar, BAY43-9006)
Subscribe
First Posted Date
2005-01-11
Last Posted Date
2013-12-13
Lead Sponsor
Bayer
Target Recruit Count
54
Registration Number
NCT00101400
Subscribe
BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients
Phase 3
Completed
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
Drug: Copaxone
Subscribe
First Posted Date
2004-12-16
Last Posted Date
2008-12-19
Lead Sponsor
Bayer
Target Recruit Count
2244
Registration Number
NCT00099502
Subscribe
Prev
1
159
160
161
162
163
Next
Β© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy